177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial

著者: Sarennya Pathmanandavel, Megan Crumbaker, Andrew O. Yam, Andrew Nguyen, Christopher Rofe, Elizabeth Hovey, Craig Gedye, Edmond M. Kwan, Christine Hauser, Arun Azad, Peter Eu, Andrew Martin, Anthony M. Joshua, Louise Emmett - Journal of Nuclear Medicine 2021 被引用: 48

Background: 177 Lutetium PSMA-617 (Lu-PSMA-617) is an effective therapy for metastatic castrate-resistant prostate cancer (mCRPC). However, treatment resistance occurs frequently and combination therapies may improve outcomes. We report the final safety and efficacy results of a phase I/II study combining Lu-PSMA-617 with idronoxil (NOX66), a radiosensitiser, and examined potential clinical, blood-based and imaging biomarkers.